CRD-4730 for Catecholaminergic Polymorphic Ventricular Tachycardia
(CPVT Trial)
Trial Summary
Will I have to stop taking my current medications?
You can continue taking your current anti-arrhythmic medications, except for amiodarone, as long as the doses have been stable for at least 4 weeks before the study.
How is the drug CRD-4730 different from other treatments for catecholaminergic polymorphic ventricular tachycardia?
CRD-4730 is a novel treatment being tested for catecholaminergic polymorphic ventricular tachycardia, a condition that currently relies on β-blockers and implantable cardioverter-defibrillators (ICDs) for management. Unlike existing treatments, CRD-4730 may offer a new approach, potentially targeting different mechanisms or providing an alternative for patients who do not respond well to current therapies.12345
What is the purpose of this trial?
This is a Phase 2, multicenter, double-blind, sponsor unblinded, placebo-controlled, single-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 when administered as single oral doses to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). The study will have 2 cohorts in which participants with CPVT will participate in a 3-period, randomized 2-sequence study. Each participant will receive 2 different doses of CRD-4730 and 1 dose of matching placebo, with each study drug administered as a single dose.
Research Team
Jason Homsy, M.D., Ph.D.
Principal Investigator
Executive Medical Director
Eligibility Criteria
Adults over 18 with confirmed CPVT, a heart condition causing irregular rapid heartbeats, can join. They must be able to do an exercise test and have been on stable doses of anti-arrhythmic meds (except amiodarone) for 4 weeks. Participants need to follow strict birth control rules.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 2 different doses of CRD-4730 and 1 dose of matching placebo, each as a single dose
Follow-up
Participants are monitored for safety and effectiveness after treatment, including changes in vital signs, ECG, and laboratory assessments
Treatment Details
Interventions
- CRD-4730
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cardurion Pharmaceuticals, Inc.
Lead Sponsor